天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (5): 455-459.doi: 10.11958/20192931

• 综述 • 上一篇    下一篇

miR-27a在妇科肿瘤中的研究进展 #br#

李圃 1，杜晓琴 2
  

  1. 天津市中心妇产科医院
  • 收稿日期:2019-09-23 修回日期:2020-01-21 出版日期:2020-05-15 发布日期:2020-06-24
  • 通讯作者: 李圃 E-mail:2326791@qq.com

Research progress of miR-27a in gynecological tumors

LI Pu1，DU Xiao-qin2 #br#   

  • Received:2019-09-23 Revised:2020-01-21 Published:2020-05-15 Online:2020-06-24

PDF (PC)

4338

摘要： 微小 RNA（miRNA）是一类内源性的非编码小 RNA，通常可通过特异性降解 mRNA或抑制蛋白质的翻译，
在转录后水平调控靶基因的表达，参与机体的多个生理或病理过程。miRNA可通过调节癌基因和抑癌基因的表达
来参与肿瘤的发生发展，在不同类型的肿瘤中及肿瘤的不同发展阶段，miRNA分子的表达谱呈现不同的特征。其
中，miR-27a定位于人类 19号染色体，在子宫内膜癌、宫颈癌、卵巢癌等多种妇科肿瘤中异常表达。本文对 miR-27a
在子宫内膜癌、宫颈癌和卵巢癌中的作用及其临床应用进展进行综述，为开发新型的肿瘤分子标志物或靶向药物提
供理论依据。

关键词: miR-27a, 妇科肿瘤, 综述

Abstract: MicroRNAs (miRNAs)，a class of endogenous small non-coding RNAs, generally regulate gene expressions
at post-transcriptional level through mRNA degradation or translation inhibition. miRNAs are involved in multiple
physiological or pathological processes. miRNA can regulate the expression of oncogene and tumor suppressor gene to
participate in the development of tumor. Different types or different stages of tumors show distinct miRNA expression
profiles, which imply the potential applications of miRNAs. miR-27a is located at human chromosome 19 and shows
dysregulated expressions in endometrial cancer, ovarian cancer, cervical cancer and many other diseases. In this review, we
summarized the research progress of miR-27a in human gynecological tumors, providing novel insights on the development
of tumor biomarkers or therapeutic agents.

Key words: miR-27a；gynecological tumor, review